All In Biotech

Drug Trial Radar · NCT04036682

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

284

Planned (sponsor's estimate)

Start

Oct 31, 2019

Primary completion

Oct 13, 2025

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Cullinan Therapeutics Inc.Industry
Sponsor type
Industry
Collaborators
Taiho Oncology, Inc.
First posted
Jul 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and evaluate efficacy.

Conditions

  • Non Small Cell Lung Cancer
  • EGFR Exon 20 Mutation

Interventions

  • CLN-081Drug

    CLN-081 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All Cohorts: The rate and severity of treatment emergent AEs.Time frame: 24 months
  2. All Cohorts: The rate and severity of DLTs.Time frame: 24 months
  3. Phase 2 Dose Expansion Cohorts: Overall response rate (ORR)Time frame: 24 months
  4. Module A: Pharmacokinetic (PK) parameterTime frame: 24 months
  5. Module A: Pharmacokinetic (PK) parameterTime frame: 24 months
  6. Module B and C: Confirmed overall response rate (ORR) and duration of response (DOR) by independent review committee (IRC)Time frame: 24 months

Locations

64 sites in 9 countries. Site status is shown where the registry gives one.

  • Pacific Cancer Medical Center, Inc

    Anaheim, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • City of Hope at Irvine Lennar

    Irvine, California

  • Pacific Shores Medical Group

    Long Beach, California

  • AdventHealth

    Orlando, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan Health System - University Hospital

    Ann Arbor, Michigan

  • Summit Medical Group PA

    Florham Park, New Jersey

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island

    Mineola, New York

  • New York University Langone Health

    New York, New York

  • Columbia University Irving Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

  • Providence Cancer Center

    Portland, Oregon

  • Providence Oncology & Hematology Care Clinic-Westside

    Portland, Oregon

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Hong Kong University - Queen Mary Hospital

    Hong Kong, Hong Kong

  • Azienda Ospedaliero Universitaria Careggi

    Careggi, Italy

  • Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I

    Marche, Italy

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS

    Meldola, Italy

  • IRCCS-Istituto Europeo di Oncologia

    Milan, Italy

  • Azienda Ospedaliero Universitaria Modena

    Modena, Italy

  • San Gerardo Hospital

    Monza, Italy

  • Ospedale Santa Maria delle Croci

    Ravenna, Italy

  • National Cancer Center Hospital East

    Chiba, Japan

  • Niigata Cancer Center

    Niigata, Japan

  • Osaka City General Hospital

    Osaka, Japan

  • Osaka International Cancer Institute

    Osaka, Japan

  • Shizuoka Cancer Center

    Shizuoka, Japan

  • National Cancer Center Hospital

    Tokyo, Japan

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    Tokyo, Japan

  • The Netherlands Cancer Institute (NKI)

    Amsterdam, Netherlands

  • Leiden University Medical Center

    Leiden, Netherlands

  • Singapore Clinical Research Institute

    Singapore, Singapore

  • National Cancer Centre Singapore

    Singapore, Singapore

  • National Cancer Center

    Goyang-si, South Korea

  • Seoul National University Bundang Hospital (SNUBH)

    Gyeonggi-do, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.